Search results
Author(s):
Meriem Perona
,
Amanda Cooklin
,
Christopher Thorpe
,
et al
Added:
1 year ago
Author(s):
Harold Bays
Added:
4 months ago
ADA 2025 - Once-monthly MariTide treatment demonstrates around 15% average weight reduction at 52 weeks in patients with obesity, with or without type 2 diabetes.We are joined by Dr Harold Bays (L-MARC Research Center, Louisville, US) to discuss a 52-week, placebo-controlled, phase 2 randomised study (NCT05669599) investigating the efficacy, safety and tolerability of different doses of once…
View more
Author(s):
Erin A Bohula
,
Harriette Van Spall
Added:
3 days ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
AHA 23: The ORFAN Study
Author(s):
Charalambos Antoniades
Added:
1 year ago
Video
Author(s):
Masahiro Natsuaki
Added:
2 years ago
ESC 23 — Dr Masahiro Natsuaki (Saga University, JP) discusses the short and optimal duration of dual antiplatelet therapy-3 Study (STOPDAPT-3) (NCT04609111).
In the STOPDAPT-2 study, 1-month dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy was shown to provide benefits in bleeding reduction over a 12-month period, however, other trials have shown high rates of bleeding at…
View more
Kalpa De Silva
Job title: Bristol Heart Institute, University Hospitals Bristol NHS Foundation Trust and University of Bristol, Bristol, UK
Author
Evangelos Giannitsis
Research Area(s) / Expertise:
Author
Expertise
Author(s):
Johanna McChord
,
Astrid Hubert
,
Udo Sechtem
,
et al
Added:
1 year ago
Simon Kennon
Research Area(s) / Expertise:
Job title: Consultant Cardiologist
Author